Other languages Erasca, Inc.

Equities

ERAS

US29479A1088

Real-time Estimate Cboe BZX Other stock markets 09:43:54 2024-05-23 am EDT			5-day change	1st Jan Change
2.615 ^USD	+7.17%		+29.10%	+14.55%

May. 21	Erasca Closes Oversubscribed Share Offering to Raise $184 Million	MT
May. 17	Erasca Acquires 2 Exclusive Worldwide Licenses for Preclinical RAS Programs	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Erasca Closes Oversubscribed Share Offering to Raise $184 Million	May. 21
Erasca Acquires 2 Exclusive Worldwide Licenses for Preclinical RAS Programs	May. 17
Erasca Prices $160 Million Common Stock Offering	May. 17
Erasca, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
Erasca, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27
Erasca, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 27
Erasca Enters Two Supply Deals With Novartis for Trametinib	Feb. 14
Erasca, Inc. Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials	Feb. 14
Erasca, Inc. Receives FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma	Dec. 11
ErascaCEO Bought Shares Worth $1,696,179, According to a Recent SEC Filing	Dec. 07
Erasca Completes Dose Escalation in Phase 1 Thunderbbolt-1 Trial; Extends Cash Runway to 2026	Nov. 28
Erasca, Inc. Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway	Nov. 28
Erasca, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Erasca Shares Jump After CEO Stock Purchase Disclosed	23-10-10
Erasca Insider Bought Shares Worth $2,026,000, According to a Recent SEC Filing	23-10-10
Erasca Doses First Patient in Trial Assessing Naporafenib Plus Trametinib in Patients With RAS Q61X Solid Tumors	23-08-29
Erasca, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Erasca Says US FDA Grants Orphan Drug Designation for ERAS-801 for Malignant Glioma	23-06-22
Erasca, Inc. Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline	23-06-05
Erasca, Inc. Announces Promising Preliminary Data for ERAS-007 Combinations in Patients with Gastrointestinal Malignancies as Part of Two Poster Presentations That Will Be Presented At the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois	23-05-25

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Erasca, Inc.

Equities

ERAS

US29479A1088

Other languages

Filters